This Wedbush analyst sees close to 200% in potential upside in Paratek Pharmaceuticals beyond the massive one-day gain on Thursday.
The U.S. Department of Health and Human Services has awarded Paratek Pharmaceuticals a pact to support development of its treatment for pulmonary anthrax.
Short sellers seem to have many emerging and speculative biotech stocks targeted for termination. Here are eight of them against which short sellers are betting the farm.
Could this small clinical-stage emerging pharmaceuticals outfit have upside of almost 200%? That's what one firm has said on the first trading day of 2019.
The top analyst upgrades, downgrades and initiations seen on Monday include AK Steel, Bloom Energy, Chipotle Mexican Grill, CIT, Cushman & Wakefield, Foot Locker, Sonos and U.S. Steel.
Paratek Pharmaceuticals saw its shares make a handy gain on Thursday after the firm announced that the FDA accepted its New Drug Application for the review of Seysara for the treatment of moderate to...
Thanks to progress made in 2017 though, it looks like 2018 could see both a radically new way of delivering antibiotics and finally the first new class approved in 30 years. Here are three companies...
24/7 Wall St. has collected several catalysts that are coming up in October for biotech and pharmaceutical companies.
24/7 Wall St. has collected several catalysts that are coming up on the calendar in the month of July and added some color.
The top analyst upgrades, downgrades and other research calls from Friday include Autodesk, IBM, Lumber Liquidators, NVIDIA, Salesforce.com, Symantec, T-Mobile and Wal-Mart.
Tuesday’s top analyst upgrades, downgrades and initiations include ADS, Swift Transportation, Seagate Technology, Synchrony Financial and United Continental.
Shares of Paratek Pharmaceuticals saw a huge gain early on Tuesday after the company provided a critical update on its late-stage pneumonia trial.
The top analyst upgrades, downgrades and initiations seen on Tuesday include Alphabet, Bank of America, Caterpillar, Nike, NVIDIA, Panera, Snap and Urban Outfitters.
A recent research report from the biotech team at Baird offers their top picks for 2017. While hardly pounding the table, they are cautiously optimistic on the industry.
Paratek Pharmaceuticals saw its shares take a solid jump early on Friday after the results from its late-stage trial were released.